» Articles » PMID: 27397505

A Landscape of Pharmacogenomic Interactions in Cancer

Abstract

Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations.

Citing Articles

Characterization of Exhausted T Cell Signatures in Pan-Cancer Settings.

Juthi R, Sazed S, Mareboina M, Zaravinos A, Georgakopoulos-Soares I Int J Mol Sci. 2025; 26(5).

PMID: 40076932 PMC: 11899893. DOI: 10.3390/ijms26052311.


Systematic Comparison of FBS and Medium Variation Effect on Key Cellular Processes Using Morphological Profiling.

Lebedev T, Mikheeva A, Gasca V, Spirin P, Prassolov V Cells. 2025; 14(5).

PMID: 40072065 PMC: 11898771. DOI: 10.3390/cells14050336.


Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

Espin R, Medina-Jover F, Siguenza-Andrade J, Farran-Matas S, Mateo F, Figueras A NAR Cancer. 2025; 7(1):zcaf007.

PMID: 40061566 PMC: 11886861. DOI: 10.1093/narcan/zcaf007.


Genomic alterations in the WNT/β-catenin pathway and resistance of colorectal cancer cells to pathway-targeting therapies.

Voutsadakis I Explor Target Antitumor Ther. 2025; 6:1002295.

PMID: 40061138 PMC: 11886378. DOI: 10.37349/etat.2025.1002295.


DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis.

Liu W, Li J, Tang Y, Zhao Y, Liu C, Song M Nat Commun. 2025; 16(1):2256.

PMID: 40050282 PMC: 11885830. DOI: 10.1038/s41467-025-57430-4.


References
1.
Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

2.
Ross D, Scherf U, Eisen M, Perou C, Rees C, Spellman P . Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000; 24(3):227-35. DOI: 10.1038/73432. View

3.
Soda M, Choi Y, Enomoto M, Takada S, Yamashita Y, Ishikawa S . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153):561-6. DOI: 10.1038/nature05945. View

4.
Godin-Heymann N, Ulkus L, Brannigan B, McDermott U, Lamb J, Maheswaran S . The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther. 2008; 7(4):874-9. DOI: 10.1158/1535-7163.MCT-07-2387. View

5.
Stratton M, Campbell P, Futreal P . The cancer genome. Nature. 2009; 458(7239):719-24. PMC: 2821689. DOI: 10.1038/nature07943. View